AKT1 and lung adenocarcinoma: Some studies have shown that the mTOR/PI3K/AKT signaling pathway is involved in the synergistic inhibition of lenalidomide and gefitinib on lung adenocarcinoma (LUAD) progression and the reduction of gefitinib resistance [17].